Beck Bode LLC Buys 1,484 Shares of Illumina, Inc. $ILMN

Beck Bode LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 51.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,342 shares of the life sciences company’s stock after purchasing an additional 1,484 shares during the period. Beck Bode LLC’s holdings in Illumina were worth $344,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Rakuten Securities Inc. lifted its position in Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 270 shares during the period. Center for Financial Planning Inc. bought a new stake in Illumina during the first quarter worth about $33,000. Fourth Dimension Wealth LLC bought a new stake in Illumina during the fourth quarter worth about $40,000. PFS Partners LLC boosted its stake in Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after acquiring an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC boosted its stake in Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after acquiring an additional 292 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 0.8%

ILMN opened at $99.54 on Thursday. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The business has a 50-day moving average of $98.74 and a 200-day moving average of $88.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market capitalization of $15.30 billion, a PE ratio of 12.60, a price-to-earnings-growth ratio of 2.22 and a beta of 1.37.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the business earned $0.36 EPS. The business’s quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ILMN shares. Piper Sandler dropped their price objective on shares of Illumina from $190.00 to $185.00 and set an “overweight” rating on the stock in a research note on Thursday, May 15th. Evercore ISI boosted their price objective on shares of Illumina from $116.00 to $128.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Royal Bank Of Canada lifted their target price on shares of Illumina from $118.00 to $126.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Scotiabank cut shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 target price for the company. in a report on Friday, July 11th. Finally, Stephens set a $110.00 target price on shares of Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $123.17.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.